High throughput screening promises to help both drug discovery and therapeutic response to personalized medicine. A challenge to the development of tissue constructs is the lack of an effective noninvasive assay that is capable to monitor cellular anatomy and physiology. The major limitation of efficacy testing in in vitro models is the cost and inefficiency of histologic preparation. Our group has recently developed a confocal imaging approach to create images that mimic the contrast mechanisms and even the appearance of standard Hematoxylin and eosin-stained histology nondestructively on whole tissue specimens. Our technique, which is noninvasive and relatively easy to perform, may enable high-throughput cellular analysis of 3D bioprinted skin constructs (3DBPS) such that longitudinal drug screening experiments can be supported. Although 3DBPS can test a variety of disease models and drug targets, we will begin working with squamous cell carcinoma (SCC) as a model, based on our experience in this area. This project builds and characterizes a 3DBPS model of SCC, defines imaging biomarkers for SCC as verified by histology in order to characterize treatment by known chemotherapeutic agents, and monitors drug response using the imaging biomarkers defined for SCC 3DBPS. Data generated will be used as a standard to rapidly and non-destructively screen novel, potential cancer anti-cancer drugs. Successful completion of this project will yield a new drug discovery platform for rapid, parallel and massive testing of chemotherapeutic agents.

Public Health Relevance

Life-saving drugs can be developed faster if we create methods to test them in studies that do not involve testing them on people. This project develops the ability to create living skin-like specimens in the laboratory and also develops the methods to test drugs on these specimens. Biology and imaging are combined in this study to produce an artificial environment where we can challenge real human diseases with many different drugs at the same time to effectively determine which drugs work best overall and which drugs are likely to work best for specific people.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Research Demonstration--Cooperative Agreements (U18)
Project #
1U18TR002312-01
Application #
9472656
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Rudnicki, Dobrila Doda
Project Start
2017-09-20
Project End
2019-06-30
Budget Start
2017-09-20
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Dermatology
Type
Graduate Schools
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065